



## LEGENDS TO SUPPLEMENTARY FIGURES

**Supplementary Fig.1.** Levels of Hsp90, AhR, p23 and XAP-2 are unaffected by treatment with HDAC inhibitors or silencing of HDAC6. A, cell lysates (100  $\mu$ g) from MSK-Leuk1 and A549 cells were subjected to western blotting with antibodies to Hsp90, AhR, p23, HDAC6, XAP-2 and  $\beta$ -actin. B, MSK-Leuk1 cells were treated with vehicle (Control), TSA (500 nM), SAHA (20  $\mu$ M) or tubacin (20  $\mu$ M) for 1 h. Cell lysates were prepared and then subjected to immunoblotting and probed with antibodies to Hsp90, AhR, p23, HDAC6, XAP-2 and  $\beta$ -actin. C, cell lysates were prepared from A549 cells stably expressing pSUPER (Control) or HDAC6 siRNA (HDAC6 KD). D, cell lysates were prepared from MSK-Leuk1 cells transiently transfected with nonspecific (control) siRNA or HDAC6 siRNA. In C and D, cell lysates were subjected to immunoblotting and probed for Hsp90, AhR, p23, HDAC6, XAP-2 and  $\beta$ -actin. E, cell lysates were prepared from MSK-Leuk1 cells that received vehicle (control) or TSA (500 nM) for 1 h or were transfected with nonspecific siRNA (control siRNA) or HDAC6 siRNA. Cell lysates were prepared and then subjected to immunoblotting and probed with antibodies to Hsp90, AhR, p23, HDAC6, XAP-2 and  $\beta$ -actin.

**Supplementary Fig.2.** Treatment with broad-spectrum HDAC inhibitors or tubacin stimulates the acetylation of Hsp90. MSK-Leuk1 cells were treated as indicated with vehicle (C), TSA (500 nM), SAHA (20  $\mu$ M) or tubacin (20  $\mu$ M) for 1 h. Cell lysates (250  $\mu$ g) were then subjected to immunoprecipitation with antibody to Hsp90. The immunoprecipitates were then subjected to immunoblotting and probed for AcK. Cell lysates were also directly subjected to immunoblotting for Hsp90.



Suppl. Fig.1



Suppl.Fig.2